The spectrum of neuropsychiatric phenomena observed in amyotrophic lateral sclerosis (ALS) is wide and not fully understood. Disorders of laughter and crying stand among the most common manifestations. The aim of this study is to report the results of an educational consensus organized by the Brazilian Academy of Neurology to evaluate the definitions, phenomenology, diagnosis, and management of the disorders of laughter and crying in ALS patients. Twelve members of the Brazilian Academy of Neurology - considered to be experts in the field - were recruited to answer 12 questions about the subject. After exchanging revisions, a first draft was prepared. A face-to-face meeting was held in Fortaleza, Brazil on 9.23.22 to discuss it. The revised version was subsequently emailed to all members of the ALS Scientific Department from the Brazilian Academy of Neurology and the final revised version submitted for publication. The prevalence of pseudobulbar affect/pathological laughter and crying (PBA/PLC) in ALS patients from 15 combined studies and 3906 patients was 27.4% (N = 1070), ranging from 11.4% to 71%. Bulbar onset is a risk factor but there are limited studies evaluating the differences in prevalence among the different motor neuron diseases subtypes, including patients with and without frontotemporal dementia. Antidepressants and a combination of dextromethorphan and quinidine (not available in Brazil) are possible therapeutic options. This group of panelists acknowledge the multiple gaps in the current literature and reinforces the need for further studies.
Background/Objectives: Hereditary transthyretin amyloidosis (ATTRv) is an autosomal dominant disorder characterized by systemic deposition of amyloid fibrils, leading to peripheral neuropathy and multisystemic involvement. Peripheral nerve ultrasound is a promising tool for detecting structural nerve changes, yet its use in Latin American populations is limited. This study aimed to characterize nerve ultrasound findings in Brazilian patients with ATTRv. Methods: We conducted a cross-sectional study of 72 genetically confirmed ATTRv individuals from two Brazilian centers. Participants were classified into symptomatic patients with polyneuropathy (n = 31) and asymptomatic TTR variant carriers (n = 41). All participants underwent a standardized neurological examination, and nerve ultrasound was used to assess the median nerve, brachial plexus, and C6 root. Cross-sectional areas (CSAs) from the right side were used for analysis and compared to reference values. Results: Symptomatic patients showed increased CSAs in the median nerve (wrist: 10.17 mm2, arm: 9.8 mm2), C6 root (8.55 mm2), and brachial plexus (70.82 mm2; all p < 0.05), but not in the forearm. Notably, asymptomatic carriers exhibited nerve enlargement in the median nerve at the wrist, the C6 root, and the brachial plexus, despite lacking clinical signs of neuropathy. Peripheral nerve enlargement in ATTRv affects both symptomatic patients and asymptomatic carriers, with a predilection for proximal and entrapment sites. Conclusions: These findings support the utility of nerve ultrasound as a non-invasive biomarker for early nerve involvement in ATTRv. Further studies are warranted to validate its role in disease monitoring and guide therapeutic interventions, especially in genetically at-risk populations.
Myasthenia gravis is an antibody-mediated disorder of the neuromuscular junction. Fatigability and fluctuations are hallmarks of the disease, posing a challenge: evaluation through a single physical examination may not reflect disease control. A shift towards patient-reported Outcomes is a new paradigm in the current practice, and these outcomes are usually assessed through validated scales. In the present paper, we discuss some of the most used scales in the clinical practice, such as the Myasthenia Gravis Foundation of America (MGFA) scale, the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, and the 15-Item Myasthenia Gravis Quality of Life (MG-QOL15) scale. Definitions of remission, minimal manifestation, high-burden disease, highly-active disease, and others are reviewed, and correlations involving these definitions and the scales are presented. Guidance on how to assess disease severity, therapeutic response, and a rationale for treatment escalation are explored.
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
24 March 2026 in European Journal of Medical Genetics
Cranial nerve involvement in hereditary transthyretin amyloidosis (ATTRv) remains an underrecognized manifestation, particularly in carriers of atypical variants. Silva Batista et al. (2022) expanded the phenotypic spectrum of the p.Ile127Val mutation by reporting cranial neuropathies in approximately 21% of p.Ile127Val individuals. Motivated by these findings, we conducted a retrospectively analysis of our cohort of p.Ile127Val carriers followed at the Neuromuscular/Peripheral Neuropathies Unit of Hospital Geral de Fortaleza, Ceará, Brazil. This hospital is located in the same northeastern region where the original cases were first described. Among 31 p.Ile127Val carriers evaluated up to May 2025, three patients (10%) exhibited some kind of cranial nerve involvement, at a median age of 61 years, which is approximately 10 years later than previously reported. All 3 affected individuals presented with some degree of axonal peripheral neuropathy, but cardiac involvement was observed in only one case. Cranial manifestations appear to be more common in p.Ile127Val carriers than individuals with other ATTRv variants or than the same variant from other regions, which suggests the existence of a potential regional founder effect. Proposed mechanisms include amyloid fibril deposition, inflammation, fibrosis, ischemic injury to cranial nerve vasculature, and, more recently, leptomeningeal amyloid infiltration. Our findings corroborate those of Silva Batista JAD et colleagues and reinforce the importance of distinguishing ATTRv amyloidosis from bulbar motor neuron disease. Recognizing associated features such as sensory axonal neuropathy and dysautonomia in order to ensure timely intervention, which can significantly modify disease progression.